Hyaluronic Acid Market is Expected to Reach USD 13.4 Billion by 2024 Hyaluronic Acid Market 2024 | Page 2

In 2015, North America dominated the market with a revenue share of over 40%. In 2009, the first
viscosupplement Synvisc-One, by Genzyme Corporation, was approved in the U.S. and gained quick
popularity owing to its efficacy and ease of use.
Increase in understanding of aging processes coupled with the interest in dermal fillers boosted the
demand for antiaging procedures in this region. Presence of market leaders such as Genzyme Corporation
and Anika Therapeutics in this region also contributes to fueling customer awareness and acceptance as a
result of aggressive marketing strategies of these companies.
Asia Pacific is anticipated to emerge as the fastest growing region during the forecast period. The
growing geriatric population in Japan and China provides a large customer base for antiaging products
and services. Moreover, Asian population is influenced by western beauty standards and aims for
volumized appearance. This has resulted in 14% growth of dermal filler market as compared to the 7% in
North America.
Some key participants of the market are Anika Therapeutics, Inc.; Seikagaku Corporation; Galderma
S.A.; Sanofi (Genzyme); Salix Pharmaceuticals; Allergan, Inc.; F. Hoffmann-La Roche Ltd., Zimmer
Holdings, Inc.; Ferring Pharmaceuticals, Inc.; and Smith & Nephew Plc.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/hyaluronic-acidmarket-analysis-by-product-single-injection-three-injection-five-injection-by-applicationosteoarthritis-adhesive-prevention-drug-delivery-dermal-fi